In this study, we focus on SSTR4 that proved to be a promising target in the treatment of inflammation and pain-associated conditions (neuropathic pain, neurogenic inflammation, bronchial asthma, rheumatoid arthritis), Alzheimer’s disease [34,35], and depression [36,37]. Here, SSTR4 is linked to depressive symptom measurement.